Out of the12 peer-reviewed publications that we published so far this year, one gaining special attention is our observations and analysis of the clinical relevance of combined AMH and FSH levels for infertile women.
Follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH) are two common infertility tests that we use to measure female ovarian function. Usually high FSH and low AMH levels present together, indicating that a women has diminished ovarian reserve (DOR) and consequently a lower chance of getting pregnant with IVF.
Sometimes, however, women present with both their AMH and FSH levels elevated. We have known that having both levels elevated is unusual, but have not understood what this contradicting finding may mean physiologically and prognostically.
Surprisingly, our research found that women with high FSH and AMH had 4 times more eggs retrieved and were nearly twice as likely to get pregnant after IVF, when compared to women with other FSH/AMH combinations.
In May, Dr. Norbert Gleicher discussed the findings of this study in front of a live audience in our first Fertility Insights webcast. He provided a comprehensive overview of what different combinations of AMH and FSH levels could mean for women who are trying to get pregnant, for a mixed audience of both clinicians as well as patients. Following the presentation, Dr. Gleicher led a question and answers session, in which he addressed various common questions and concerns about AMH and FSH levels.
Click on the video below to view the full recorded copy of the webcast:
You can find out more information about CHR’s Fertility Insights webcasts on our webcast homepage: Webcast